Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, with 50-75% of these patients requiring renal replacement therapy (RRT). The outcome of peritoneal dialysis (PD) in ADPKD with end-disease renal disease (ESRD) is not clearly defined, more so in developing countries. We conducted a retrospective analysis of the outcomes and economics of PD in these ESRD patients and compared them with other causes of ESRD on PD. Data were reviewed of all the PD patients who were followed-up at our institute from January 2007 to December 2011. The inclusion criteria were ADPKD patients who chose PD as the dialysis modality (Group 1), while age and gender-matched ESRD (other than ADPKD) patients who were started on PD during the same period were considered as the other group (Group 2). A total of 26 ADPKD patients underwent PD with an average size of kidneys among ADPKD ESRD patients of 15.2 + 2.1 cm. The overall peritonitis rates were similar among the compared groups. The median survival for the first peritonitis episodes were 1.2 and 1.8 years (95% confidence interval 0.82-1.91) for the control and ADPKD groups, respectively. The overall patient survival was 22 among PKD while five patients died among the control group. Among PKD, one patient died due to intra-cerebral bleed while one patient had severe cyst hemorrhage and infection, while three others had peritonitis and sepsis. Hernia was observed in four ADPKD patients, once on PD that was surgically corrected and PD was resumed in all. Two patients lost the catheter due to peritonitis while one patient had membrane failure while one underwent surgical exploration due to diverticulosis. PD treatment was not prevented by voluminous kidneys in any of these patients and no patient ceased PD treatment due to insufficient peritoneal space. Besides this, the cost on PD was much less as compared with that on hemodialysis (HD). PD is a reasonable mode of RRT among ADPKD, where HD is not possible or contraindicated with lesser risks to bleeding and infections, and the cost benefit favoring PD in general.
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Anupma
A
Kaul
R
R
Dharshan
Dharmendra
D
Bhadhuaria
Narayan
N
Prasad
Amit
A
Gupta
R K
RK
Sharma
D000328:Adult; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007194:India / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018803:Models, Economic; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000191:economics* / Q000401:mortality; D016891:Polycystic Kidney, Autosomal Dominant / Q000175:diagnosis / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D017064:Process Assessment, Health Care / Q000191:economics*; D006435:Renal Dialysis / Q000191:economics; D012189:Retrospective Studies; D016896:Treatment Outcome